Lanova Medicines Announces Initiation Of Phase 1 Clinical Trial Of Anti-PD-1/VEGF Bispecific Antibody LM-299 And Completion Of $42 Million Series C1 Financing

(MENAFN - PR Newswire) Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstrating strong inhibition ...Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute